# How Institutional Investors Run Healthcare Due Diligence: The Complete Playbook > Institutional investors follow a rigorous, multi-layer due diligence process before committing capital to healthcare companies, spanning regulatory, clinical, IP, financial, and commercial domains. This explainer breaks down every stage, the exact databases to check, common mistakes to avoid, and how to do it faster with AI-powered tools. ## What Does Healthcare Due Diligence Actually Look Like at the Institutional Level? Institutional investors running healthcare due diligence work through five parallel workstreams simultaneously: regulatory risk, clinical and scientific validity, intellectual property defensibility, financial integrity, and commercial market reality. The process is not sequential. Teams assign specialists to each lane on day one, then converge findings into a consolidated risk matrix before an investment committee. The single biggest mistake smaller investors make is treating these workstreams as a checklist to complete in order, which lets fatal risks hide in untouched lanes until late in the process. ## How Do Institutional Teams Assess Regulatory Risk? Regulatory risk is the most company-specific and time-sensitive layer. Institutional analysts start with the FDA's public databases before contacting the company at all. Start here: - **FDA Drugs@FDA** (accessdata.fda.gov) for approved drugs, NDA and ANDA histories, and labeling changes - **FDA 510(k) and PMA databases** for medical devices, including post-market surveillance orders and recalls - **FDA Warning Letter database** for any enforcement actions against the company or its contract manufacturers - **FDA Establishment Inspection Reports (EIRs)**, available via FOIA, to assess manufacturing quality posture - **EU EMA public assessment reports** if the company has or seeks European approval A critical but often skipped step is reviewing the company's complete response letters and Complete Response Letters (CRLs) where publicly available. CRLs signal what the FDA found insufficient in prior submissions and reveal how management responds to regulatory setbacks, which is a direct proxy for execution quality. ## What Clinical and Scientific Diligence Do Institutional Investors Actually Run? Institutional investors do not simply read company slide decks. They triangulate company-presented data against independent sources. - Pull every listed trial from **ClinicalTrials.gov** and compare registered endpoints to what the company reports publicly. Endpoint switching between registration and publication is a significant red flag. - Search **PubMed** for peer-reviewed publications from the company's key opinion leader (KOL) network to assess whether scientific support is genuine or manufactured. - Hire independent biostatisticians or clinical consultants (often through networks like GLG or Guidepoint) to assess statistical methodology, patient population selection, and comparator arm choices. - Benchmark trial design against competitors using published literature. A trial designed to pass, rather than to generate useful clinical data, often shows up in underpowered comparator arms or composite endpoints that dilute the primary signal. For clinical-stage companies, assess probability of technical success (PTS) by indication using published FDA approval rate data by phase and therapeutic area. Investors who skip this step routinely misprice binary risk. ## How Do Institutional Investors Evaluate Intellectual Property? IP defensibility determines how long a commercial moat actually lasts. Institutional teams use the **USPTO Patent Full-Text Database** (patents.google.com or the USPTO Public PAIR system) to map every patent the company holds, when each expires, and what claims are actually broad versus narrow. Key questions: - Are the core product patents composition-of-matter patents (strongest) or method-of-use patents (easier to design around)? - Has the company filed continuation patents to extend protection, and how strong are those continuation claims? - Are there inter partes review (IPR) petitions pending at the USPTO Patent Trial and Appeal Board? Check the PTAB online system directly. - What is the realistic exclusivity window after accounting for patent expiry, pediatric exclusivity extensions, and potential generic or biosimilar entry timelines? A company showing strong revenue projections but with core patents expiring within three to four years without a pipeline replacement is a compression trade, not a growth investment. ## What Financial and Corporate Governance Checks Do Institutions Run? For publicly traded companies, institutional analysts build their financial model from **SEC EDGAR filings** directly, not from company-provided financial summaries. - Read the complete 10-K and 10-Q, not the earnings presentation. Pay particular attention to the footnotes on revenue recognition, related-party transactions, and contingent liabilities. - Review proxy statements (DEF 14A) for executive compensation structure. Companies where executives earn large bonuses on milestones they control present misalignment risk. - Check the auditor's going-concern language in the most recent 10-K. It appears in the notes section and signals runway concerns that management presentations often minimize. - For private companies, request audited financials (not reviewed or compiled), cap table with full dilution detail, and all debt instrument terms. ## How Do Institutional Investors Validate Commercial Opportunity? Market size claims in pitch decks are almost always overstated. Institutional teams build their own bottoms-up models. - Use **CMS public data** (data.cms.gov) to assess actual Medicare and Medicaid reimbursement rates and coverage policies for comparable products. - Review FDA Orange Book and published drug pricing compendia to anchor realistic pricing assumptions. - Run primary KOL interviews (5 to 15 physicians depending on the indication) to assess real-world adoption intent, competitive product satisfaction, and unmet need severity. - Model competitive dynamics using public pipeline data from ClinicalTrials.gov and competitor investor presentations to stress-test the addressable window. ## What Are the Most Common Mistakes in Healthcare Due Diligence? - Relying on company-curated data packages without independent primary source verification - Skipping manufacturing and supply chain quality assessment until post-term sheet - Treating regulatory agency feedback letters as public record when many are not, and failing to use FOIA requests to access them - Ignoring reimbursement risk until after technical risk is resolved, when both move in parallel - Missing patent cliff exposure because the team only reviewed patents the company highlighted ## Healthcare Due Diligence Checklist - [ ] FDA Warning Letters, CRLs, and EIRs pulled from primary sources - [ ] ClinicalTrials.gov registration vs. reported endpoints compared - [ ] PubMed literature review with independent scientific consultant sign-off - [ ] USPTO and PTAB patent map with expiry and IPR exposure noted - [ ] SEC EDGAR 10-K footnotes and proxy reviewed, not just summaries - [ ] CMS reimbursement data anchoring commercial model - [ ] Primary KOL interviews completed - [ ] Competitive pipeline mapped from ClinicalTrials.gov - [ ] Going-concern language and runway runway confirmed - [ ] Cap table and full dilution schedule (private companies) ## How Can You Run This Process Faster Without Sacrificing Depth? The process above, done manually, takes a seasoned team two to four weeks per target. MedFuel Intel compresses the primary-source verification layer by using AI to pull, parse, and cross-reference FDA databases, ClinicalTrials.gov, USPTO, PTAB, SEC EDGAR, and PubMed simultaneously, then flags discrepancies between company claims and primary-source data before your team spends time on them. Run a free Red Flag Screener on any healthcare company at https://medfuelintel.com and see which regulatory, clinical, IP, and financial issues surface in minutes rather than weeks. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-institutional-investors-run-healthcare-due-diligence). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.